Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

Likely Human

www.globenewswire.comby Sanofi Winthrop IndustrieMay 18, 2026Submitted May 18, 2026

ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD Data from the head-to-head study show efdoralprin alfa...

The Verdict

ClassificationLikely Human

ConfidenceMedium confidence

Analyzedtext

Community Verdict

Be the first to vote on this assessment.

Embed Badge

Add this badge to your site to show the AI classification for this content.

[![Real Press](https://real.press/api/badge/f44d64d3-5683-428c-8968-b46cf12a30c7)](https://real.press/content/f44d64d3-5683-428c-8968-b46cf12a30c7)